Effects of PHA-665752 and cetuximab combination treatment on in vitro and murine xenograft growth of human colorectal cancer cells with KRAS or BRAF mutations.

CONCLUSION: Combination treatment with PHA-665752 and cetuximab suppressed in vitro and in vivo CRC cell growth more than treatment with either agent alone did. PMID: 28359236 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28359236?dopt=Abstract

Source: Current Cancer Drug Targets - March 30, 2017 Category: Cancer & Oncology Authors: Jia YT, Yang DH, Zhao Z, Bi XH, Han WH, Feng B, Zhi J, Gu B, Duan Z, Wu JH, Ju YC, Wang MX, Li ZX Tags: Curr Cancer Drug Targets Source Type: research